What Is KPV? The Tripeptide From Alpha-MSH

What Is KPV? The Tripeptide From Alpha-MSH, Iron Rack Labs Journal cover listing six topics, from KPV’s position in alpha-MSH to what a KPV certificate should name

KPV is the tripeptide Lys-Pro-Val: residues 11 to 13 at the C terminus of alpha-MSH, a 13 residue hormone cut from the precursor pro-opiomelanocortin. As a free acid its formula is C16H30N4O4, with an average mass of 342.44 and a monoisotopic mass of 342.2267.

Three residues make KPV easy to name and hard to verify. Five other arrangements of the same residues share its exact mass, so the evidence that matters on a certificate is sequence, not mass alone.

The KPV peptide is both a short piece of a well characterized hormone and a research material catalogued on its own. This article covers its chemistry, its parent hormone, why so small a molecule is hard to characterize, how the published research is made up, where that evidence stops, and what a certificate should name. For chromatography background, see what an RP-HPLC purity number actually measures.

Scope: this article summarizes published laboratory and animal research. It does not describe or recommend use in people or animals, and the research use policy sets out how materials on this site are supplied.

What is the KPV peptide, chemically?

KPV is lysine, proline and valine joined by two peptide bonds. The human pro-opiomelanocortin record, UniProt entry P01189, describes a 267 residue precursor that contains alpha-MSH at positions 138 to 150, annotated with an N-acetylserine at its start and a valine amide at its end. KPV is the last three of those 13 residues, positions 148 to 150 of the precursor.

  • Ser
  • Tyr
  • Ser
  • Met
  • Glu
  • His
  • Phe
  • Arg
  • Trp
  • Gly
  • Lys
  • Pro
  • Val

As a standalone molecule, KPV is usually described as the free acid. The ChEBI record for Lys-Pro-Val gives the formula C16H30N4O4, an average mass of 342.440 and a monoisotopic mass of 342.22671.

Form Formula Monoisotopic mass Where it appears
KPV, free acid C16H30N4O4 342.2267 The usual standalone form
KPV amide C16H31N5O3 341.2427 Matches the amidated C terminus of alpha-MSH
Ac-KPV-NH2 C18H33N5O4 383.2533 Acetylated and amidated analog
Pro-Lys-Val C16H30N4O4 342.2267 Sequence isomer with the same mass as KPV

Masses for the amide and acetylated forms are calculated from their formulas. A 0.984 difference between acid and amide is easy to resolve by mass spectrometry, but only if the certificate states which form was expected.

Where KPV comes from

The parent hormone is alpha-melanocyte stimulating hormone. A 2008 review by Brzoska and colleagues describes alpha-MSH as a tridecapeptide derived from pro-opiomelanocortin and discusses its C terminal tripeptide, KPV, in its own right. The same review discusses a second tripeptide, KdPT, which corresponds to residues 193 to 195 of interleukin 1 beta and is described as a derivative of KPV.

Three molecules share this literature, and they are not interchangeable.

Alpha-MSH

The 13 residue parent, acetylated at the N terminus and amidated at the C terminus in the UniProt annotation.

KPV

Residues 11 to 13 of alpha-MSH, Lys-Pro-Val. Studied as a standalone tripeptide, most often as the free acid.

KdPT

Lys-D-Pro-Thr, matching residues 193 to 195 of interleukin 1 beta. A related tripeptide with a different mass, not another name for KPV.

Alpha-MSH (11-13), KPV and Lys-Pro-Val name one molecule. Analogs with a D residue or blocked ends are different compounds.

Why a three residue peptide is analytically tricky

Small does not mean simple. Checks that discriminate well on a 15 or 40 residue peptide lose resolving power at three residues.

  • Same mass, different sequence. Lys, Pro and Val can be joined in six orders. The ChEBI record for Pro-Lys-Val lists the same formula and the same monoisotopic mass, 342.22671, as KPV. A D residue at any position also leaves the mass unchanged.
  • A weak UV signal. KPV has no tryptophan, tyrosine or phenylalanine, so it absorbs very little near 280 nanometers. Detection rests on its two peptide bonds at low UV wavelengths, where solvents and counterions also absorb.
  • Little to hold on a column. With two primary amines and only one small hydrophobic side chain, KPV tends to elute early on a reversed phase column, close to unretained material.
  • Counterions carry real weight. As an illustrative calculation, one trifluoroacetate (114.02) per KPV molecule puts the peptide at about 75 percent of the salt’s mass, and two put it at about 60 percent. With acetate, the same arithmetic gives about 85 and 74 percent.
  • An end that can cyclize. KPV has proline in position 2 and a free amine at its N terminus, the layout most associated with diketopiperazine cleavage.

A 2022 kinetic study by Zhang, Hales and Clemmer notes that diketopiperazine cleavage happens most often when a peptide carries a penultimate proline and an unprotected N terminus. Its model peptides, examined in ethanol at 65 to 75 degrees Celsius, included one with lysine at position 1. KPV itself was not tested, so this is a pathway to watch for, not a measured rate; the expected products would be a cyclic Lys-Pro dipeptide and free valine. Temperature is one control on reactions like this, as covered in cold chain and why the storage temperature is on the label.

A mass match is not a sequence

An LC-MS identity check confirms that something with the mass of KPV is present. On mass alone it cannot tell Lys-Pro-Val from Pro-Lys-Val, Val-Lys-Pro or a D residue variant. Fragmentation data, or a retention match against a reference standard, does that work.

How the published research on KPV is made up

The KPV literature is small and preclinical. Three papers show its shape.

A 2008 cell and rodent study by Dalmasso and colleagues examined KPV in two human intestinal epithelial cell lines, Caco2-BBE and HT29-Cl.19A, and in human Jurkat T cells. It used radiolabeled KPV to characterize transport by PepT1, a di- and tripeptide transporter, and examined two chemically induced mouse colitis models, DSS and TNBS.

A 2008 rodent study by Kannengiesser and colleagues examined KPV in DSS colitis and CD45RBhi T cell transfer colitis in mice, and repeated the DSS model in mice carrying a nonfunctional melanocortin 1 receptor.

A 2017 formulation study by Xiao and colleagues loaded KPV into hyaluronic acid functionalized polymeric nanoparticles of about 272 nanometers and examined them in colonic epithelial cells, macrophages and a mouse colitis model. Its findings belong to that nanoparticle system, not to a lyophilized tripeptide.

Across these papers the readouts are signaling reporters, cytokine expression and tissue histology in cells and mice. None of them is a human study.

Where the evidence stops

Mouse colitis models are chemically or immunologically induced conditions in a different species, and cell lines are single cell types in a dish. Neither establishes how KPV behaves in a person.

FDA’s position is consistent with that. Its page on bulk drug substances that may present significant safety risks, content current as of April 22, 2026, lists KPV among nominations withdrawn from category 2 and states that FDA has not identified any human exposure data for it. Check the current version of that page, because the lists are revised.

KPV has since come before FDA’s advisory process. The July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting page, content current as of August 6, 2026, lists KPV related bulk drug substances, KPV free base and KPV acetate, on the July 23 agenda for discussion of the 503A bulks list.

The meeting page describes KPV as being considered for inclusion on the 503A bulks list, not as included, and neither FDA page describes KPV as an approved drug.

Two further limits apply. Work on alpha-MSH does not transfer to KPV, which lacks 10 of the parent’s 13 residues, and work on an analog such as KdPT does not transfer to the free tripeptide.

What a KPV certificate should name

For a molecule this small, the certificate carries most of the identity argument. The guide on how to read a certificate of analysis covers the general layout.

  • The sequence written out as Lys-Pro-Val
  • The C terminal form, free acid or amide
  • The molecular formula, C16H30N4O4 for the free acid
  • An observed LC-MS mass beside the calculated value
  • Evidence that separates KPV from same mass sequence isomers
  • An RP-HPLC chromatogram with its detection wavelength stated
  • The counterion, acetate or trifluoroacetate
  • A lot number and test date that match the vial label

The KPV 10mg listing sits in the short chain peptides category. Iron Rack Labs publishes a lot matched certificate for its materials in the certificate of analysis library, and the quality and testing page sets out the methods behind it: RP-HPLC for purity and LC-MS for identity. Pick a KPV lot there and check that the observed mass sits at 342.23 as the neutral molecule or 343.23 as the singly protonated ion, that the chromatogram names its detection wavelength, and that the counterion is stated.

Research material

KPV 10mg

Lys-Pro-Val, C16H30N4O4, supplied for research use only. Each lot has a matched certificate in the certificate of analysis library.

View KPV 10mg
The short version

  • KPV is Lys-Pro-Val, residues 11 to 13 of alpha-MSH
  • The free acid is C16H30N4O4, monoisotopic mass 342.2267
  • Five sequence isomers share that exact mass
  • Published research is cell, rodent and formulation work, with no human studies
  • FDA states it has identified no human exposure data for KPV
  • A certificate should name the sequence, C terminal form and counterion

Frequently asked questions

The KPV peptide is the tripeptide Lys-Pro-Val, the last three residues of alpha-MSH, a 13 residue hormone processed from pro-opiomelanocortin. As a free acid it has the formula C16H30N4O4 and a monoisotopic mass of 342.2267. Published research on it consists of cell, rodent and formulation studies.

Yes. KPV matches residues 11 to 13 of alpha-MSH, the C terminal end of the hormone. Alpha-MSH has 13 residues with an acetylated N terminus and an amidated C terminus, while KPV is usually catalogued as a free acid. Research on alpha-MSH does not transfer to the tripeptide.

Because its mass does not pin down its sequence. Lys, Pro and Val can be joined in six orders, and every one has the same formula and monoisotopic mass. KPV also lacks aromatic residues, so its UV signal is weak, and it tends to elute early on reversed phase columns. Identity needs fragmentation data or a reference standard match, not mass alone.

No FDA page describes KPV as an approved drug. FDA’s category 2 page, content current as of April 22, 2026, lists KPV among withdrawn nominations and states that FDA has not identified human exposure data for it. A July 23, 2026 advisory committee agenda listed it as being considered for the 503A bulks list. Check FDA’s current pages for later action.

No. KdPT is Lys-D-Pro-Thr, which corresponds to residues 193 to 195 of interleukin 1 beta and is described in the literature as a derivative of KPV. It has threonine in place of valine, a D proline and a different mass.

Sources

  1. Pro-opiomelanocortin, entry P01189. UniProtKB, entry version 239, September 2, 2026. View source
  2. Lys-Pro-Val, CHEBI:160254. ChEBI, European Bioinformatics Institute. View source
  3. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M, 2008. Review. Endocrine Reviews, 29(5), 581 to 602. DOI
  4. Pro-Lys-Val, CHEBI:162495. ChEBI, European Bioinformatics Institute. View source
  5. Zhang Z, Hales DA, Clemmer DE, 2022. Analytical study. Journal of the American Society for Mass Spectrometry, 33(8), 1368 to 1376. DOI
  6. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D, 2008. Cell and rodent study. Gastroenterology, 134(1), 166 to 178. DOI
  7. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T, 2008. Rodent study. Inflammatory Bowel Diseases, 14(3), 324 to 331. DOI
  8. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D, 2017. Formulation study. Molecular Therapy, 25(7), 1628 to 1640. DOI
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, content current as of April 22, 2026. View source
  10. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration, content current as of August 6, 2026. View source

Journal article titles are not reproduced in this list. Each entry links to the original record.

This article is general educational information about published laboratory research. It is not medical, legal or regulatory advice, and nothing in it describes or recommends the use of any compound in people or animals. Materials supplied by Iron Rack Labs are for research use only: not for human or veterinary use, not for diagnostic use, and not for use as a food, drug, dietary supplement or cosmetic. Sale is restricted to adults aged 18 or over. Iron Rack Labs publishes this Journal and supplies research materials, and nothing in this article is an offer, a recommendation or an instruction for use. See the compliance overview for details.